Quick Answer
Cytosorbents Corp reported Net Income Loss of -$8.20 million for the year ending 2025.
- Cytosorbents Corp showed an increase of +60.4% in Net Income Loss from 2024 to 2025.
- This data is from Cytosorbents Corp's annual report (Form 10-K), filed with the SEC on March 30, 2026.
- XBRL data for this metric is available from 2007 to 2025 (19 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2013: -$1.63 million | Q2 2013: -$1.41 million | Q3 2013: -$964.8 thousand | Q1 2014: -$975.1 thousand | Q2 2014: -$1.85 million | Q3 2014: -$1.50 million | Q1 2015: -$4.72 million | Q2 2015: $1.43 million | Q3 2015: -$2.85 million | Q1 2016: -$1.84 million | Q2 2016: -$3.01 million | Q3 2016: -$2.19 million | Q1 2017: -$1.52 million | Q2 2017: -$1.73 million | Q3 2017: -$2.05 million | Q1 2018: -$2.98 million | Q2 2018: -$5.82 million | Q3 2018: -$3.00 million | Q1 2019: -$4.88 million | Q2 2019: -$3.55 million | Q3 2019: -$6.89 million | Q1 2020: -$3.45 million | Q2 2020: -$2.87 million | Q3 2020: -$839.7 thousand | Q1 2021: -$4.17 million | Q2 2021: -$4.68 million | Q3 2021: -$6.41 million | Q1 2022: -$8.97 million | Q2 2022: -$10.88 million | Q3 2022: -$12.20 million | Q1 2023: -$7.33 million | Q2 2023: -$6.15 million | Q3 2023: -$9.19 million | Q1 2024: -$6.09 million | Q2 2024: -$4.29 million | Q3 2024: -$2.77 million | Q1 2025: -$1.48 million | Q2 2025: $1.95 million | Q3 2025: -$3.17 million.
- Over the full 19 years of available data (2007 to 2025), Cytosorbents Corp's Net Income Loss has declined by 144.7%.
- Historical annual values: Fiscal year 2025: -$8.20 million | Fiscal year 2024: -$20.72 million | Fiscal year 2023: -$29.25 million | Fiscal year 2022: -$32.81 million | Fiscal year 2021: -$24.56 million | Fiscal year 2020: -$7.84 million | Fiscal year 2019: -$19.27 million | Fiscal year 2018: -$17.21 million | Fiscal year 2017: -$8.46 million | Fiscal year 2016: -$11.76 million | Fiscal year 2015: -$9.48 million | Fiscal year 2014: -$9.32 million | Fiscal year 2013: -$4.68 million | Fiscal year 2012: -$3.66 million | Fiscal year 2011: -$5.48 million | Fiscal year 2010: -$2.91 million | Fiscal year 2009: -$2.74 million | Fiscal year 2008: -$3.02 million | Fiscal year 2007: -$3.35 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: